Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the ...

Pratteln, Switzerland, March 27, 2025 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming Annual General Meeting to be held on May 20, ...

Santhera Pharmaceuticals to share latest on rollout of AGAMREE and future strategic priorities: Pratteln, Switzerland Thursday, March 27, 2025, 13:00 Hrs [IST] Santhera Pharmaceut ...

Pratteln, Switzerland, March 27, 2025 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming Annual General Meeting to be held on ...

Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress ...

(RTTNews) - Santhera Pharmaceuticals reported total revenue from contracts with customers of 39.1 million Swiss francs compared to 103.4 million francs, prior year. Product sales were 14.8 million ...

Catherine Isted, an experienced healthcare CFO with over 25 years in life sciences, appointed as CFO effective February 24, 2025 Current CFO Andrew Smith to step down after five years with ...

Santhera has reached an agreement with health insurance funds in Germany on reimbursement of its Agamree treatment for Duchenne muscular dystrophy (DMD) that should support broad use of the drug.